Production of a multimeric protein by cell fusion method

ABSTRACT

The present invention features a method of producing a multimeric protein from a hybrid cell formed from the fusion of two or more cells, each of which cell is engineered to express one component of the multimeric protein, as well as a method for screening for successful fusion of the cells to produce a desired hybrid cell. The methods of the invention are widely applicable to the production of proteins having two or more components.

FIELD OF THE INVENTION

This invention relates generally to methods for use in gene expressionand cell fusion techniques, particularly in the production ofmulti-component proteins.

BACKGROUND OF THE INVENTION

Recombinant DNA techniques have been used for production of heterologousproteins in transformed host cells. Generally, the produced proteins arecomposed of a single amino acid chain or two chains cleaved from asingle polypeptide chain. More recently, multichain proteins such asantibodies have been produced by transforming a single host cell withDNA sequences encoding each of the polypeptide chains and expressing thepolypeptide chains in the transformed host cell (U.S. Pat. No.4,816,397).

The basic immunoglobulin (Ig) structural unit in vertebrate systems iscomposed of two identical “light” polypeptide chains (approximately 23kDa), and two identical “heavy” chains (approximately 53 to 70 kDa). Thefour chains are joined by disulfide bonds in a “Y” configuration, andthe “tail” portions of the two heavy chains are bound by covalentdisulfide linkages when the immunoglobulins are generated either byhybridomas or by B cells.

A schematic of the general antibody structure is shown in FIG. 1. Thelight and heavy chains are each composed of a variable region at theN-terminal end, and a constant region at the C-terminal end. In thelight chain, the variable region (termed “V_(L)J_(L)”) is the product ofthe recombination of a V_(L) gene to a J_(L) gene. In the heavy chain,the variable region (V_(H)D_(H)J_(H)) is the product of recombination offirst a D_(H) and a J_(H) gene, followed by a D_(H)J_(H) to V_(H)recombination. The V_(L)J_(L) and V_(H)D_(H)J_(H) regions of the lightand heavy chains respectively, are associated at the tips of the Y toform the antibody's antigen binding domain and together determineantigen binding specificity.

The (C_(H)) region defines the antibody's isotype, i.e., its class orsubclass. Antibodies of different isotypes differ significantly in theireffector functions, such as the ability to activate complement, bind tospecific receptors (Fc receptors) present on a wide variety of celltypes, cross mucosal and placental barriers, and form polymers of thebasic four-chain IgG molecule.

Antibodies are categorized into “classes” according to the C_(H) typeutilized in the immunoglobulin molecule (IgM, IgG, IgD, IgE, or IgA).There are at least five types of C_(H)genes (Cμ, Cγ, Cδ; Cε, and Cα),and some species (including humans) have multiple C_(H) subtypes (e.g.,Cγ₁, Cγ₂, Cγ₃, and Cγ₄ in humans). There are a total of nine C_(H) genesin the haploid genome of humans, eight in mouse and rat, and severalfewer in many other species. In contrast, there are normally only twotypes of light chain constant regions (C_(L)), kappa (κ) and lambda (λ),and only one of these constant regions is present in a single lightchain protein (i.e., there is only one possible light chain constantregion for every V_(L)J_(L) produced). Each heavy chain class can beassociated with either of the light chain classes (e.g., a C_(H)γ regioncan be present in the same antibody as either a κ or λ light chain).

A process for the immortalization of B cell clones producing antibodiesof a single specificity has been developed involving fusing B cells fromthe spleen of an immunized mouse with immortal myeloma cells. Singleclones of fused cells secreting the desired antibody could then beisolated by drug selection followed by immunoassay. These cells weregiven the name “hybridoma” and their antibody products termed“monoclonal antibodies.”

The use of monoclonal antibodies as therapeutic agents for human diseaserequires the ability to produce large quantities of the desiredantibody. One approach to increased production was simply to scale upthe culture of hybridoma cells. Although this approach is useful, it islimited to production of that antibody originally isolated from themouse. In the case where a hybridoma cell produces a high affinitymonoclonal antibody with the desired biological activity, but has a lowproduction rate, the gene encoding the antibody can be isolated andtransferred to a different cell with a high production rate.

In some cases it is desirable to retain the specificity of the originalmonoclonal antibody while altering some of its other properties. Forexample, a problem with using murine antibodies directly for humantherapy is that antibodies produced in murine systems may be recognizedas “foreign” proteins by the human immune system, eliciting a responseagainst the antibodies. A human anti-murine antibody (HAMA) responseresults in antibody neutralization and clearance and/or potentiallyserious side-effects associated with the anti-antibody immune response.Such murine-derived antibodies thus have limited therapeutic value.

One approach to reducing the immunogenicity of murine antibodies is toreplace the constant domains of the heavy and light chains with thecorresponding human constant domains, thus generating human-murinechimeric antibodies. Chimeric antibodies are generally produced bycloning the antibody variable regions and/or constant regions, combiningthe cloned sequences into a single construct encoding all or a portionof a functional chimeric antibody having the desired variable andconstant regions, introducing the construct into a cell capable ofexpressing antibodies, and selecting cells that stably express thechimeric antibody. Examples of methods using recombinant DNA techniquesto produce chimeric antibodies are described in PCT Publication No. WO86/01533 (Neuberger et al.), and in U.S. Pat. No. 4,816,567 (Cabilly etal.) and U.S. Pat. No.5,202,238 (Fell et al.).

In another approach, complementarity determining region (CDR)—graftedhumanized antibodies have been constructed by transplanting the antigenbinding site, rather than the entire variable domain, from a rodentantibody into a human antibody. Transplantation of the hypervariableregions of an antigen-specific mouse antibody into a human heavy chaingene has been shown to result in an antibody retainingantigen-specificity with greatly reduced immunogenicity in humans(Riechmann et al. (1988) Nature 332:323-327; Caron et al. (1992) J. Exp.Med 176:1191-1195).

Another approach in the production of human antibodies has been thegeneration of human B cell hybridomas. Applications of human B cellhybridoma-produced monoclonal antibodies have promising potential in thetreatment of cancer, microbial infections, B cell immunodeficienciesassociated with abnormally low antibody production, and other diseasesand disorders of the immune system. Obstacles remain in the developmentof such human monoclonal antibodies. For example, many human tumorantigens may not be immunogenic in humans and thus it may be difficultto isolate anti-tumor antigen antibody-producing human B cells forhybridoma fusion.

For a given disease indication, one antibody isotype is likely to begreatly preferred over another. The preferred isotype may vary from oneindication to the next. For example, to treat cancer it may be desirablethat the binding of an antibody to a tumor cell result in killing of atumor cell. In this case, an IgG1 antibody, which mediates bothantibody-dependent cellular cytotoxicity and complement fixation, wouldbe the antibody of choice. Alternatively, for treating an autoimmunedisease, it may be important that the antibody only block binding of aligand to a receptor and not cause cell killing. In this case, an IgG4or IgG2 antibody would be preferred. Thus, even in a situation where ahigh affinity, antigen-specific, fully human antibody has been isolated,it may be desirable to re-engineer that antibody and express the newproduct in a different cell.

The growing use of phage display technology also points to a need forantibody engineering and expression methodologies. Phage displaytechnology is used for producing libraries of antibody variable domainscloned into bacteria. This allows variable domains of desiredspecificity to be selected and manipulated in vitro. While bacteriaoffer a great advantage for selecting and producing antibody fragments,they are not capable of producing full-size intact antibodies in nativeconfiguration, and it is necessary to reconstitute fragments selected inbacteria into intact antibodies and express them in eucaryotic cells.

SUMMARY OF THE INVENTION

The present invention features a method of producing a multimericprotein from a hybrid cell formed from the fusion of two or more cells,each of which cell is engineered to express one component of themultimeric protein, as well as a method for screening for successfulfusion of the cells to produce a desired hybrid cell. The methods of theinvention are widely applicable to the production of proteins having twoor more components.

In one specific application of the method of the invention, themultimeric protein is an antibody composed of antigen-specific heavy andlight chains. DNA encoding the desired heavy chain (or a fragment of theheavy chain) is introduced into a first mammalian host cell, while DNAencoding the desired light chain (or a fragment of the light chain) isintroduced into a second mammalian host cell. The first transformed hostcell and the second transformed host cell are then combined by cellfusion to form a third cell. Prior to fusion of the first and secondcells, the transformed cells may be selected for specifically desiredcharacteristics, e.g., high levels of expression. After fusion, theresulting hybrid cell contains and expresses both the DNA encoding thedesired heavy chain and the DNA encoding the desired light chain,resulting in production of the multimeric antibody.

In one aspect the invention features the multimeric protein produced bythe method of the invention. In one embodiment, the invention includesan antibody produced by the method of the invention.

In another aspect the invention features a method for screening forsuccessful fusion of a first cell, containing a first nucleotidesequence encoding a desired antibody heavy chain and a second cellcontaining a second nucleotide sequence encoding a desired antibodylight chain, the method comprising including a nucleotide sequenceencoding a first marker gene in the first cell, including a nucleotidesequence encoding a second marker gene in the second cell, fusing thefirst and second cells to produce a fused cell and assaying for thepresence of the first and second marker genes in the fused cell.

One advantage of the method of the invention is that cells expressing asingle component of the final multi-component protein can beindividually selected for one or more desired characteristics, such as ahigh rate of production.

Another advantage is that the method generates a cell which produces anantibody at a multiplication high rate through the fusion of two kindsof cells which are each selected prior to fusion for high production ofthe desired heavy or light chains.

Another advantage is that the final multi-component protein is notexpressed until all the cells expressing the individual components ofthe multi-component protein are fused into a single hybrid cell.

Other aspects, features, and advantages of the invention will becomeapparent from the following detailed description, and the claims.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a schematic showing the basic immunoglobulin structure.

FIG. 2 is a flow chart showing one embodiment of the method of inventionwhen mammalian cells are separately transformed with the desired lightand heavy chain DNA, then fused to form the hybrid cell expressing bothchains.

FIG. 3 illustrates a specific embodiment of the invention in which amammalian cell expressing an irrelevant light chain is transformed withthe desired heavy chain DNA, a second mammalian cell is transformed withthe desired light chain DNA, and the desired hybrid cell formed fromfusion of the transformed host cells is selected which expresses thedesired antibody product.

FIG. 4 is a schematic illustrating a specific embodiment of theinvention in which DHFR CHO cells are independently transfected with (i)pManuGamma#6, a human heavy chain Ig construct and (ii) pManuKappa#14, ahuman light chain Ig construct. The independent cell lines are selected,amplified, fused, and selected to yield a hybrid cell containing thehuman heavy chain Ig construct and the human light chain Ig construct.

FIG. 5 is a schematic diagram of a fusion method in accordance with thepresent invention demonstrating the use of HPRT and LacZ marker genesfor the initial determination of the success of a fusion process.

DETAILED DESCRIPTION

Before the methods and compositions of the present invention aredescribed and disclosed it is to be understood that this invention isnot limited to the particular methods and compositions described as suchmay, of course, vary. It is also to be understood that the terminologyused herein is for the purpose of describing particular embodimentsonly, and is not intended to be limiting since the scope of the presentinvention will be limited only by the appended claims.

It must be noted that as used in this specification and the appendedclaims, the singular forms “a”, “an” and “the” include plural referencesunless the context clearly dictates otherwise. Thus, for example,reference to “a DNA sequence” includes a plurality of DNA sequences anddifferent types of DNA sequences.

Unless defined otherwise all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although any materials ormethods similar or equivalent to those described herein can be used inthe practice or testing of the present invention, the preferred methodsand materials are now described. All publications mentioned herein areincorporated herein by reference for the purpose of describing anddisclosing the particular information for which the publication wascited. The publications discussed above are provided solely for theirdisclosure prior to the filing date of the present application. Nothingherein is to be construed as an admission that the inventor is notentitled to antedate such disclosure by virtue of prior invention.

Definitions

By the term “nucleotide sequence” is meant any DNA fragment of interestwhich may be introduced into a cell, including an intact gene orfragment of a gene. When the method of the invention is used to generatean antibody, the nucleotide sequence of interest will be all or part ofeither the constant region and/or variable region of the light or heavychains, and may include all, part, or none of the regulatory nucleotidesequences that control expression of the light or heavy chain. Thenucleotide sequence of interest for heavy chains includes but is notlimited to all or a portion of the V, D, J, and switch regions(including intervening sequences) and flanking sequences. For lightchains, the nucleotide sequence of interest includes but is not limitedto the V and J regions, and flanking and intervening sequences. Thenucleotide sequence may be a naturally occurring sequence, synthetic, orpartially natural and partially synthetic. The sequence may also be anon-naturally occurring or modified naturally-occurring sequence. TheDNA sequence includes sequences taken from different sources, e.g.,different species. For example, when the method is used to produce anantibody, the DNA chain may encode a chimeric (for example, human-mouse)immunoglobulin chain, or it may be a CDR-grafted DNA sequence having ahuman immunoglobulin sequence with antigen-specific murine CDRsequences. The DNA of the nucleotide sequence may encode a fully humanantibody. B-cells obtained from non-human animals immunized with anantigen and also hybridoma, trioma, and quadromas derived from suchB-cells can also provide the nucleotide sequence introduced into thehost cells. B-cells and hybridomas producing any kind of monoclonalantibody may be used as a source of the nucleotide sequence, includingcells producing, for example, fully mouse monoclonal antibodies, fullyhuman monoclonal antibodies, CDR-grafted monoclonal antibodies, chimericmonoclonal antibodies, and F(ab)₂.

By the terms “multi-component”, “multichain”, or “multimeric” protein ismeant a protein composed of two or more proteins or polypeptides. Themethod of the invention is useful for producing a multimeric protein bythe fusion of two or more cells each expressing a single component ofthe multimeric protein. For example, in one embodiment themulti-component protein is an antibody generated from two heavy chainsencoded by DNA transfected into a first cell and two light chainsencoded by DNA transfected into a second cell, where the finalmultimeric antibody is produced by a hybrid cell formed from the fusionof the first and second cells. “Multi-component,” “multichain,” and“multimeric” protein is meant to include any heterodimeric orhetero-oligomeric protein (e.g., BMP2/BMP7 heterodimeric osteogenicprotein, ICE (interleukin-1 converting protein), receptors of thenucleus (e g., retinoid receptors), heterodimeric cell surface receptors(e.g., T cell receptors), integrins (e.g., cell adhesion molecules,β₁-integrins, (see, e.g., Hynes, 1987 Cell 48:549-554; Hynes 1992 Cell60:11-25), tumor necrosis factor (TNF) receptor, and soluble-andmembrane-bound forms of class I and class II MHC (majorhistocompatibility complex proteins). Where the multimeric protein is areceptor, “multimeric protein” is meant to encompass soluble andmembrane forms of the receptor.

By the term “introducing” a nucleotide sequence into a cell meansinserting an exogenous piece of DNA into a cell, including but notlimited to transfection or transduction with a vector, such that all orpart of the exogenous nucleotide sequence is stably maintained in thecell, and the resulting transformed cell expresses the introducednucleotide sequence.

By the term “fusing” or “fusion” of two or more cells is meant a methodin which two or more cells are combined to form a single hybrid cellwhich contains all or part of at least the nucleic acid content of eachindividual cell. Fusion may be accomplished by any method of combiningcells under fuseogenic conditions well known in the art (See, forexample, Harlow & Lane (1988) in Antibodies, Cold Spring Harbor Press,New York). Known methods for fusing cells includes by use withpolyethylene glycol (PEG) or Sendai virus.

By the term “hybrid cell” is meant a cell formed by combining two ormore cells, e.g., by fusion. In the method of the invention, hybridcells are formed from the fusion of one or more transformed cells eachexpressing a single component of a multimeric protein.

The term “irrelevant” as in, e.g., “an irrelevant light chain” means alight chain which does not contribute to the binding of the antigen ofinterest and is not a component of the multimeric protein produced bythe hybrid cell of the invention.

By the term “desired” component, e.g., desired heavy chain, or desiredlight chain, is meant an immunoglobulin chain which recognizes theantigen of interest.

Generation of a Hybrid Cell Producing a Heterologous Multimeric Protein

The present invention provides a method for generating a hybrid cellproducing a multi-component protein from two or more transformed cellseach of which cells produces a single component of the multimericprotein. This method features several important advantages relative toconventional methods for protein production. For example, the method ofthe present invention allows separately transformed cells to beindividually selected for optimal expression of each component of themulti-component protein. This selection occurs prior to fusion of cellsforming the hybrid cell and prior to production of the final multimericprotein. The method of the invention results in a final multi-componentprotein product which is not expressed until a single hybrid cell isproduced from the fusion of each cell expressing a component of thefinal protein product.

Generally, when the multi-component protein to be produced is anantibody, the method of the invention involves generation of a cellexpressing a desired heavy chain, generation of a cell expressing adesired light chain, and fusion of the two cells to form a hybrid cellexpressing the final antibody protein (FIG. 2). Generation of a cellexpressing the desired heavy chain involves the following steps: (1)identifying and cloning and/or synthesizing the gene, gene fragment, ornucleotide sequence encoding the variable segment or antigen-bindingsequences of the heavy chain. The nucleotide sequence may be obtainedfrom either a cDNA or genomic source, or synthesized de novo; (2)cloning the nucleotide sequence encoding the desired constant regions ofthe heavy chain; (3) ligating the variable region with the constantregion so that the complete nucleotide sequence can be transcribed andtranslated to express the desired heavy chain polypeptide; (4) ligatingthe construct into a vector containing a selectable marker andappropriate gene control regions; (5) amplifying the construct inbacteria; (6) introducing the vector into eukaryotic cells; (7)selecting the cells expressing the selectable marker; and (8) screeningthe cell supernatants or lysates for the expressed heavy chain.Similarly, a cell expressing a desired light chain construct isgenerated as outlined above.

Alternatively, the process of generating a cell expressing a desiredheavy or light chain may involve (1) construction of a Ig chain DNAsequence containing (a) a signal sequence, (b) the gene, gene fragment,or nucleotide sequence encoding the variable region or antigen-binding.sequences, and (c) the nucleotide sequence encoding the desired constantregion of the Ig chain, followed by (2) PCR amplification of the Igconstruction, (3) insertion of the construct into eukaryotic cells, (4)selecting the cells expressing the selectable marker, and (5) screeningthe cells for the expressed Ig chain. Optionally, the cells expressingthe desired heavy chain or the desired light chain can be furtherselected for desirable characteristics, such as heavy or light chainproduction rate or level, ability of the expressed heavy or light chainto combine with another light or heavy chain, respectively, to providean antibody having a desired antigen binding affinity, and/or othercharacteristics desirable for heavy or light chain production orfunction in an antibody.

Transformed cells expressing or capable of expressing the desiredcomponent of the multimeric protein are fused by methods known in theart to form a hybrid cell expressing the multimeric protein. When themultimeric protein is an antibody, the DNA sequences encoding thedesired immunoglobulin may be composed entirely of sequences originatingfrom a single species, e.g., fully human or fully murine, or may becontain sequences originating from more than one species, e.g., ahuman-mouse chimera or CDR-grafted humanized antibody. The hybrid cellproduced antibody product may also contain a desired antigen bindingsite (variable region) linked to a desired constant region. Thus, aspecifically designed antibody may be generated with a desiredantigenicity combined with the desired isotype.

Prior art methods for independently expressing the light and heavychains in a single host cells are known, see, for example, U.S. Pat. No.4,816,397, European patent application publication No. 88,994, PCTpublished patent application WO 93/19172, U.S. Pat. No. 4,816,567, U.S.Pat. No. 4,975,369, U.S. Pat. No. 5,202,238, PCT published patentapplication WO 86/01533, PCT published patent application WO 94/02602,and European published patent application No. 273,889.

Vector Constructs

The vectors of the invention are recombinant DNA vectors including, butnot limited to, plasmids, phages, phagemids, cosmids, viruses,retroviruses, and the like, which insert a nucleotide sequence into acell.

Methods for introducing an exogenous nucleotide sequence of interestinto a cell, including into antibody-producing cells, are known in theart. These methods typically include use of a DNA vector to introducethe nucleotide sequence into the genome or a cell or cells, and thengrowing the cells to generate a suitable population. Nucleotidesequences may also be introduced directly into a cell by methods knownin the art.

In a preferred embodiment, nucleotide sequences are introduced intomammalian cells according to the CaPO₄ transfer procedure described byGraham and van der Eb (1973) Virology 52:456-467, herein specificallyincorporated by reference. Transfection of mammalian cell lines may beaccomplished by any of a number of methods known to those skilled in theart, including but not limited to, CaPO₄ precipitation, electroporation,microinjection, liposome fusion, RBC ghost fusion, protoplast fusion,and the like.

DNA Sequences

The nucleotide sequence encoding a component of the desiredmulti-component protein may be obtained as a cDNA or as a genomic DNAsequence by methods known in the art. For example, messenger RNA codingfor a desired component may be isolated from a suitable source employingstandard techniques of RNA isolation, and the use of oligo-dT cellulosechromatography to segregate the poly-A mRNA. When the productmulti-component protein is an antibody, suitable sources of desirednucleotide sequences may be isolated from mature B cells or a hybridomaculture.

In addition to the nucleotide sequence encoding the desired component ofthe product multi-component protein, vector constructs can includeadditional components to facilitate replication in prokaryotic and/oreukaryotic cells, integration of the construct into a eukaryoticchromosome, and markers to aid in selection of and/or screening forcells containing the construct (e.g., the detectable markers and drugresistance genes discussed above for the targeting construct). Foreukaryotic expression, the construct should preferably additionallycontain a polyadenylation sequence positioned 3′ of the gene to beexpressed. The polyadenylation signal sequence may be selected from anyof a variety of polyadenylation signal sequences known in the art.Preferably, the polyadenylation signal sequence is the SV40 earlypolyadenylation signal sequence.

Transformation of Host Cells

Antibodies have been expressed in a variety of host cells, includingbacterial, yeast, and insect cells. For the production of large,multimeric proteins, mammalian cell expression systems generally providethe highest level of secreted product (Bebbington (1991) Methods: ACompanion to Methods Enzymol. 2:136-145). Myeloma cells have been usedas fusion partners for splenic cells to generate hybridomas cellsexpressing antibodies. Transformed myeloma cells may be used as fusablehost cells in the method of the invention.

Host Cells

Nonlymphoid cells lines have been investigated for use in producingantibodies (Cattaneo & Neuberger (1987) EMBO J. 6:2753-2758; Deans etal. (1984) Proc. Natl. Acad. Sci. 81:1292-1296; Weidle et al. (1987)Gene 51:21-2.9). The ability of nonlymphoid cell lines to assemble andsecrete fully functional antibodies may be exploited for antibodyproduction. For example, Chinese hamster ovary (CHO) cells and COS cellshave well-characterized efficient expression systems and have been usedfor both long-term and transient expression of a variety of proteins(Bebbington (1991) supra). A method for achieving a high level ofexpression of DNA sequences encoding a chimeric antibody in transformedNSO myeloma cells has been described (Bebbington et al. (1992)Bio/Technology 10:169-175).

Any mammalian cell line capable of expressing the desired multimericprotein and amenable to fusion is suitable for use in the presentinvention. For example, where the desired protein is an antibody, thecell line is any mammalian cell capable of expressing a functionalantibody. A preferred host cell is a mammalian myeloma cell; mostpreferably, an non-secreting (NS) myeloma cell (e.g., a non-secreting(NSO) myeloma). Other myeloma cells include mouse derivedP3/X63-Ag8.653, P3/NS1/1-Ag4-1(NS-1), P3/X63Ag8.U1 (P3U1), SP2/O-Ag14(Sp2/O, Sp2), PAI, F0, and BW5147; rat derived 210RCY3-Ag.2.3; and humanderived U-266AR1, GM1500-6TG-A1-2, UC729, CEM-AGR, DIR11, and CEM-T15.

Selection of Transformed Cells

Detection of transfectants with properly integrated vector sequences canbe accomplished in a number of ways, depending on the nature of theintegrated sequences. If the transferred nucleotide sequence includes aselectable marker, the initial screening of the transfected cells is toselect those which express the marker. Any of a variety of selectablemarkers known in the art may be included in the construct, includingdihydrofolate reductase (DHFR), guanosine-phosphoryl transferase gene(gpt), neomycin resistance gene (Neo), hygromycin resistance gene (Hyg)and hypoxanthine phosphoribosyl transferase (HPRT). For example, whenusing a drug resistance gene, those transfectants that grow in theselection media containing the drug (which is lethal to cells that donot contain the drug resistance gene) can be identified in the initialscreening. It will be appreciated that a variety of other positive, aswell as negative (i.e., HSV-TK, cytosine deaminase, and the like),selectable markers that are well known in the art can be utilized inaccordance with the present invention for selection of specific cellsand. transfection or other events. As well, a variety of other markergenes (i.e, the LacZ reporter gene and the like) can be utilized insimilar manners.

After a period of time sufficient to allow selection to occur (in mostcases, about 2 weeks) the surviving cells are then subjected to a secondscreening to identify those transfectants which express the desiredpeptide component of interest. This may be accomplished by, forinstance, an immunoassay using antibodies specific for the particularimmunoglobulin class.

The protocol for the second screening depends upon the nature of theinserted sequences. For example, where the cell is transformed with asequence which does not result in a secreted product, selection for thepresence of the foreign DNA can be detected by Southern blot using aportion of the exogenous sequence as a probe, or by polymerase chainreaction (PCR) using sequences derived from the exogenous sequence asamplifiers. The cells having an appropriately integrated sequence canalso be identified by detecting expression of a functional product,e.g., immuno-detection of the product. Alternatively, the expressionproduct can be detected using a bioassay to test for a particulareffector function conferred by the exogenous sequence.

Where the first host cell is transfected with DNA encoding heavy chain,the expression of the heavy chain can be tested using any conventionalimmunological screening method known in the art, for example, ELISAconducted with cell lysate samples (see, for example, Colcher et al.Protein Engineering 1987 1:499-505) The cell can be further selected foradditional desirable characteristics such as heavy chain production rateor level, ability of the expressed heavy chain to combine with lightchain to provide an antibody of a desired antigen binding affinity, andother characteristics desirable for heavy chain production and heavychain function in an antibody.

Nonlymphoid cells expressing a desired protein may be transfected in anumber of ways known to the art. One example of the method of theinvention is described in Example 1 below. A first CHO cell may betransfected with a vector comprising a DNA sequence encoding a desiredlight chain and a second CHO cell transfected with a vector comprising aDNA sequence encoding a desired heavy chain. Transfected cells areselected and fused. Fused cells are selected for expression of anantibody having the desired light chain Ig and heavy chain Ig.

In one embodiment, a cell expressing an Ig heavy chain gene alsoexpresses an irrelevant Ig light chain gene. In some instances,co-expression of a light chain may be required for secretion andexpression of the Ig heavy chain. Failure of a cell to secrete the heavychain peptide may make detection of transfectants more difficult sinceit necessitates assaying the cells themselves (e.g., by Northern blotanalysis or immuno-detection), as opposed to conveniently screening thecell supernatant by ELISA.

In a specific embodiment of the invention, this problem is avoided bytransfecting a first host cell expressing an irrelevant light chain witha plasmid bearing the desired heavy chain (FIG. 3). The gene encodingthe irrelevant light chain may either be integrated into a chromosome orbe present in an episomal vector, such as bovine papilloma virus (BPV)or other episomal vector known in the art. After selection fortransformants, expression of the heavy chain is easily confirmed by anELISA assay of the cell lysates for secreted antibody.

Cells expressing the desired heavy chain are then fused with a secondcell that has been transfected with the desired light chain underappropriate fuseogenic conditions according to methods well known in theart (see, e.g., Harlow & Lane, supra) Any combination OL cells capableof expressing a desired heavy chain or desired light chain and that canbe fused to produce a hybrid cell expressing both heavy and light chainscan be used. Thus, the first cell (e.g., expressing the desired heavychain) can be of the same or different type as the second cell (e.g.,expressing the desired light chain), e.g., the first cell can be amyeloma cell and the second cell can be a non-lymphoid cell. The fusionproduct cells which are candidates for manufacturing lines will expressthe desired heavy chain and light chain, but will have lost theirrelevant light chain. During the fusion process, random chromosomesare normally lost. Thus, it is expected that cells lacking theirrelevant Ig light chain will be generated during the fusion process.These hybrid cells can easily be identified by. ELISA assay of thesupernatants for the presence of the desired chains and absence of theirrelevant chain.

Thus, in one embodiment, the desired light chain of the final antibodyproduct is the κ light chain. In such cases, a Igλ expressing myelomacell is transfected with the desired IgH gene. After transfection with aplasmid carrying the desired heavy chain and selection, cells expressingthe heavy chain are examined directly for expression of the desiredheavy chain, e.g., ELISA assay of the supernatants with antibodyspecific to the heavy chain. The second cell, e.g., a non-secretingmyeloma cell, is, transfected with the κ light chain, and transfectantsdetected through e.g., Northern blot analysis or immuno-detection withan antibody specific to the κ light chain. The cells expressing thelight chain can be further selected for desirable characteristicsassociated with production of a functional light chain, such as lightchain production rate or level, ability of the expressed light chain tocombine with heavy chain to provide an antibody of a desired antigenbinding affinity, and other characteristics desirable for light chainproduction and heavy chain function in an antibody. The cells are thenfused, and the hybrid cell expressing the desired IgH/IgK antibody isselected for the presence of the κ light chain and desired heavy chain(e.g., C_(γ)) and the absence of λ light chain, e.g., by ELISA assay ofthe culture medium.

When the desired product antibody contains λ light chain, the first celltransfected with DNA encoding the desired heavy chain will express a κlight chain, and final selection of hybrid cells expressing the desiredantibody will select for the presence of the λ light chain and theabsence of the κ light chain.

In an alternative embodiment of the invention, selection of fused orhybrid cells can be initially determined through the utilization ofdistinct marker genes in each of the “parental” cells or cell lines.Such technique is shown in FIG. 4. There, a parental CHO cell line, thatis DHFR, is transfected with a vector (pManu Kappa) that contains theDHFR resistance gene and the hygromycin resistance gene (HYGRO). Anotherparental CHO cell line, that is DHFR, is transfected with a vector(pManu Gamma) that contains the DHFR resistance gene and the neomycinresistance gene. Each cell line, following transfection, containsdistinct selectable markers (i.e., hygromycin resistance in the firstand neomycin/G418 resistance in the second). Thus, upon fusion,resulting “daughter” cells in which fusion has been successful will beresistant to both hygromycin and G418. The screening technique of theinvention is advantageous in that it mitigates the need to determineexpression of immunoglobulin molecules in order to determine if a fusionhas been successfully performed.

Under certain fusion conditions, cells and cell lines can becomespontaneously resistant to G418, and, possibly, other selectablemarkers. Thus, in certain embodiments of the invention, it is preferableto utilize selectable markers to which cells and cell lines are lesslikely to spontaneously generate resistance. An example of one suchmarker is the hypoxanthine phosphoribosyl transferase gene (HPRT) whichconfers resistance to hypoxanthine aminopterin. Another marker that canbe used in tandem with HPRT resistance is the LacZ gene. The LacZ geneis not a selectable marker; but, rather, acts as a marker gene which,when expressed by a cell, stains blue in the presence ofβ-galactosidase.

Thus, through following a similar scheme as described in connection withFIG. 4, a first parental cell line, which is HPRT deficient (such as theP3X, NSO, and NSO-bcl2 myeloma cell lines), is transfected with anantibody gene cassette. The cassette includes, for example, appropriateantibody genes, a gene amplification system, and an HPRT selectablemarker. Transfected cells can be selected through HPRT selection andcells producing high levels of antibodies can be picked. A secondparental cell line, which is also preferably HPRT deficient, istransfected with an antibody gene cassette. The cassette includes, forexample, appropriate antibody genes, a gene amplification system, andthe LacZ gene. Transfected cells can be selected through staining withβ-gal. As will be appreciated, either the first or second parental cellline can include the light chain genes or the heavy chain genes and theother of the first or second parental cell line will contain the otherof the light or heavy chain genes. As will also be appreciated, otherselectable markers can be included in the cassettes utilized totransfect the cells. Upon fusion of the first and second parental celllines, successful fusion can be determined through HPRT selection andβ-gal staining of daughter cells. Daughter cells can be further selectedbased upon expression levels of immunoglobulin molecules.

Specific embodiments of this technique is illustrated in FIG. 5 inseveral exemplary schemes. In the Figure, a first parental cell line,exemplified by the myeloma cell line, NSO, which is HPRT deficient, istransfected with a light chain cassette containing a gene amplificationsystem (AM), an antibody light chain gene system (V_(K)J_(K)C_(K)), andan HPRT selectable marker (HPRT) (Step 1). A second parental cell line,exemplified by any one of J558L, Ag.1, or NSO, are transfected with aheavy chain cassette containing a gene amplification system (AM), anantibody heavy chain gene system (V_(H)D_(H)J_(H)h_(γ)), and the LacZgene (Step 2). The transfection of J558L cell line is indicated as Step2a, the transfection of the Ag.1 cell line is indicated as Step 2b, andthe transfection of the NSO cell line is indicated as Step 2c. Withrespect of each Step 1 and Steps 2a-2c, the success of the transfectioncan be determined through the use of the selectable marker HPRT in Step1 and through β-gal staining in connection with each of Steps 2a-2c.Additionally cells can be picked for expression of light chain (Step 1)or heavy chain (Step 2a-2c).

Following isolation and generation of parental cell lines incorporatingthe antibody gene cassettes, fusion between a parental cell lineincluding heavy chain genes and a parental cell line including lightchain genes is conducted. Utilizing techniques described herein, theparental cell line resulting from Step 1 is fused with a parental cellline resulting from Steps 2a-2c. This is indicated in the Figure asfusion 1-2a, fusion 1-2b, and fusion 1-2c, which results in fused cells1-2a, 1-2b, and 1-2c, respectively. Such fused cells can be readilyidentified through dual marker selection, that is, HPRT selection andβ-gal staining. Cells which have been successfully fused, will be HPRTresistant and will stain positive with β-gal.

As will be appreciated, the parental cell lines utilized in fusions 1-2aand 1-2b additionally contain mouse mλ and rat γκ genes. Thus, daughtercells from fusions 1-2a and 1-2b are preferably selected to ensure thatthey are mλ and γκ. Loss of mouse mλ genes and rat γκ genes willgenerally occur naturally through recombination events during the fusionprocess.

EXAMPLES

The following examples are put forth so as to provide those of ordinaryskill in the art with a complete disclosure and description of how tomake and use various constructs and perform the various methods of thepresent invention and are not intended to limit the scope of what theinventors regard as their invention. Unless indicated otherwise, partsare parts by weight, temperature is in degrees centigrade, and pressureis at or near atmospheric pressure. Efforts have been made to ensureaccuracy with respect to numbers used, (e.g., length of DNA sequences,molecular weights, amounts, particular components, etc.) but somedeviations should be accounted for.

Example 1 Generation of Hybrid Cells Containing Light and Heavy IgChains

The human heavy chain Ig construct (IgH gamma) was ligated into thepManugamma#6 vector (FIG. 4; Cell Genesys, Inc., Foster City, Calif.)containing DHFR and neo marker genes. The human kappa light chain Igconstruct was ligated into the pManukappa#14 (FIG. 4; Cell Genesys,Inc.) which contains DHFR and hygromycin resistance marker genes.

Overview of the Cell Fusion Method

In general, the experiment proceeds as follows: A first cell istransfected with the pManukappa vector comprising the human kappa lightchain transgene, and MTX and hygromycin selection marker genes. A secondcell is transfected with the pManugamma vector comprising a human γ₄heavy chain transgene and Neo and MTX selectable marker genes. After theappropriate selection and amplification, the selected first and secondcells are fused to form the hybrid cell of the invention expressing ahuman antibody.

Cell Transfection

Chinese hamster ovary (CHO) cells are transfected by electroporation asfollows: DHFR-deficient CHO cells in exponential growth are fed withgrowth medium 4 hours prior to electroporation [growth medium:DMEM/Ham's F12 (50:50 mixture; JRH BioSciences, Woodland, Calif.), 10%FBS, 2 mM glutamine, non-essential amino acids (NEAA) plus glycine,hypoxanthine and thymidine (GHT)]. Cells are collected, washed in PBS,and resuspended in PBS to a concentration of 5×10⁶ cells per 0.8 ml. Thecell suspension is aliquoted into 0.4 cm electroporation cuvettes (0.8ml per cuvette) and 5-20 ug linearized DNA added. The suspension ismixed and left on ice for 10 min. Each cuvette is electroporated at 260V and 960 uF. Each cuvette is place on ice for 10 min, the cellsresuspended in 20 ml growth medium, then plated onto 2 10 cm cellculture plates. After 48 hrs, cells from each culture plate are replatedin 10 culture plates in the presence of selective media [DMEM, 4.5 g/lglucose (JRH Biosciences), 10% dialyzed FBS (Life Technologies,Bethesda; Md.), 5 mM glutamine, NEAA, 0.6 mg/ml G418].

Selection of Transfectants

Cells transfected with the kappa light chain transgene were selected-inthe presence of methotrexate (MTX) and hygromycin. Cells were plated 48hr post-electroporation into 10 plates in DHFR selective media [DMEM,4.5 g/l glucose (JRH Biosciences), 10% dialyzed FBS (Life Technologies,Bethesda, Md.), 5 mM glutamine, NEAA, supplemented with hygromycin(Calbiochem, San Diego, Calif.) at, concentrations ranging from 250-750ug/ml]. Recombinant protein expression can be increased by DHFR-mediatedamplification of the transfected gene. Methods for selecting cell linesbearing gene amplifications are known in the art, e.g., for example, asdescribed in Ausubel et al. (1989) Current Protocols in MolecularBiology, John Wiley & Sons, New York; such methods generally involveextended culture in medium containing gradually increasing levels ofmethotrexate.

Heavy chain transfectant CHO cells are selected in the presence of MTXand neomycin following the above described procedures.

Generation of a Hybrid Cell Expressing an Antibody

Prior to fusion, PEG/DMSO fusion solution (50% PEG, 10% DMSO in PBS)(Sigma) is placed in a 37° C. incubator overnight, and 500-1000 mlincomplete Ham's F12 solution (without FCS) is filtered. At fusion, warmfusion medium and incomplete DMEM/Hams' F12 are placed in a 37° C. waterbath. A water-filled beaker and a 15 ml conical tube filled withincomplete DMEM/Ham's F12 are also placed in the water bath. Harvestedtransfected CHO cells are washed once with incomplete DMEM/Ham's F12,pelleted at 1200 rpm, resuspended in incomplete DMEM/Ham's F12, andcounted. The kappa light chain and the γ₄ transfected cells are mixed ina 1:1 ratio, and centrifuged at 800×g (2060. rpm). The following fusionsteps are followed: (1) add 1 ml PEG/DMSO fusion solution to cells over1 min period; (2) stir cells gently for 1 min; (3) add 2 ml incompleteDMEM/Ham's F12 over a 2 min period with slow stirring; and (4) add 8 mlof incomplete DMEM/Ham's F12 over a 3 min period with slow stirring. Thecells are then centrifuged at room temperature at 400×g for 5 min (1460rpm). Selection medium [complete DMEM/Ham's F12+10% FCS+250-750 ug/mlhygromycin+0.6 mg/ml G418] is added to the cell pellet. 10 ml ofselection medium are added to the cell pellet; cells are gently stirredto resuspend.

The cells are plated onto 10 cm dishes as dilutions of 1:10, 1:20, and1:40 in selection medium. The plates are refed with fresh medium every 3days until clones appear. Clones are picked and transferred to a 96-wellplate in selection medium. As will be appreciated, growth of cells toreach confluence, which demonstrates survival of cells through selectionwith hygromycin and G418, is indicative that the cells contain both theheavy and light chain Ig genes, since hygromycin resistance wascontributed by the light chain gene containing parental cells andneomycin resistance was contributed by the heavy chain gene containingparental cells. As such, dual marker selection provides an expedientmethod to initially determine whether a fusion has been successfullyaccomplished. Following such an initial screen, supernatant can beassayed for expression of the desired antibody as described below. Whenthe wells are confluent, the supernatant is assayed for expression ofthe desired antibody as described below.

Selection for Desired Hybrid Cell

Expression of the desired antibody may be assayed by immunologicalprocedures, such as Western blot or immunoprecipitation analysis ofhybrid cell extracts, or by immunofluorescence of intact cells (using,e.g., the methods described in Ausubel et al. (1989) supra). The desiredantibody is detected using antibody specific for each component of thedesired antibody, e.g., antibodies specific to the kappa light chain andγ₄ heavy chain.

Confirmation of Desired Characteristics of Antibody Produced by HybridCell

After the hybrid cell is produced and antibody production in the cell isconfirmed, the hybrid cell is grown under conditions to allow expressionof the antibody and secretion of the antibody into the cell culturesupernatant. For example, the cells can be grown in roller bottles inselective growth medium (DMEM/Ham's F12 (50:50 mixture), 10% FBS, 2 mMglutamine, non-essential amino acids plus glycine, hypoxanthine andthymidine, plus hygromycin and G418 to provide continued selection forthe heavy and light chain constructs in the hybrid cell) for severalhours prior to assay. Cell culture supernatant is collected and theantibodies are tested for various desired characteristics, e.g., antigenbinding affinity (e.g., preferably antigen binding affinity that issimilar to that of the original antibody from which the recombinantantibody is derived) using immunological assays well known in the art(e.g., ELISA, or competition binding assays)

The instant invention is shown and described herein in what isconsidered to be the most practical and the preferred embodiments. It isrecognized, however, that departures may be made therefrom which arewithin the scope of the invention, and that obvious modifications willoccur to one skilled in the art upon reading this disclosure.

1. A method for producing a human antibody, said method comprising: (a) introducing a first polynucleotide into a first mammalian myeloma cell, wherein the first polynucleotide comprises a first amplifiable marker and a sequence encoding a heavy chain polypeptide of a human antibody; (b) introducing a second polynucleotide into a second mammalian myeloma cell, wherein the second polynucleotide comprises a second amplifiable marker and a sequence encoding a light chain polypeptide of said human antibody; (c) culturing each of said first and second mammalian myeloma cells separately in the presence of an amplification agent, wherein the first and second amplifiable markers are the same; and (d) fusing the cultured cells produced by steps (a)-(c) to form a hybrid cell, wherein the hybrid cell expresses said human antibody; wherein the first cell expresses an irrelevant light chain and expresses the heavy chain prior to fusion with the second cell.
 2. The method of claim 1, further comprising: (e) recovering the human antibody from the hybrid cell.
 3. The method of claim 1, wherein the first cell and second cell are NSO cells.
 4. The method of claim 1, wherein the first and second amplifiable markers are each dihydrofolate reductase (DHFR), glutamine synthase, or adenosine deaminase.
 5. A method for producing a human antibody, said method comprising: (a) culturing a first recombinant mammalian myeloma cell in the presence of a first amplification agent to produce a first amplified recombinant cell; wherein the first cell comprises a first polynucleotide comprising a first amplifiable marker and a sequence encoding a heavy chain polypeptide of a human antibody, (b) culturing a second recombinant mammalian myeloma cell in the presence of a second amplification agent to produce a second amplified recombinant cell; wherein the second cell comprises a second polynucleotide comprising a second amplifiable marker and a sequence encoding a light chain polypeptide of said human antibody, wherein the first and second amplifiable markers are the same; and (c) fusing the first and second amplified recombinant mammalian myeloma cells to form a hybrid cell, wherein the hybrid cell expresses said human antibody; wherein said human antibody is produced, and wherein the first cell expresses an irrelevant light chain and expresses the heavy chain prior to fusion with the second cell.
 6. The method of claim 5, further comprising: (d) recovering the antibody from the hybrid cell.
 7. The method of claim 5, wherein the first cell and second cell are NSO cells.
 8. The method of claim 5, wherein the polynucleotide encoding the heavy chain polypeptide and the polynucleotide encoding the light chain polypeptide are obtained from a B-cell or a hybridoma cell, wherein said B-cell or hybridoma cell produce an antibody.
 9. The method of claim 5, wherein the first cell expressing the desired heavy chain is selected for one or more desirable characteristics prior to said fusing.
 10. The method of claim 5, wherein the second cell expressing the desired light chain is selected for one or more desirable characteristics prior to said fusing.
 11. The method of claim 9, wherein said desirable characteristic is a high production rate of the heavy chain.
 12. The method of claim 10, wherein said desirable characteristic is a high production rate of the light chain.
 13. The method of claim 5, wherein the first and second amplifiable markers are each dihydrofolate reductase (DHFR), glutamine synthase (GS), or adenosine deaminase. 